We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+11.25%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$311M
AUM Growth
+$69M
(+29%)
Cap. Flow
+$46.5M
Cap. Flow
% of AUM
14.94%
Top 10 Holdings %
Top 10 Hldgs %
34.58%
Holding
105
New
32
Increased
29
Reduced
26
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Universal Health Services
UHS
|
+$11.2M |
| 2 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
+$7.93M |
| 3 |
VWR
VWR Corporation
VWR
|
+$6.84M |
| 4 |
CTLT
CATALENT, INC.
CTLT
|
+$6.5M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
+$5.82M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
STJ
St Jude Medical
STJ
|
+$9.69M |
| 2 |
Encompass Health
EHC
|
+$5.34M |
| 3 |
SHPG
Shire pic
SHPG
|
+$4.9M |
| 4 |
McKesson
MCK
|
+$4.57M |
| 5 |
HOLX
Hologic
HOLX
|
+$3.28M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.32% |
| 2 | Financials | 3.19% |
| 3 | Industrials | 2.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Regeneron Pharmaceuticals
REGN
$78.5B
| $504K | 0.16% |
1,300
-900
| -41% | -$334K |
|
77
Regenxbio
RGNX
$620M
| $479K | 0.15% |
+24,800
| New | +$478K |
|
78
BioMarin Pharmaceuticals
BMRN
$11.6B
| $448K | 0.14% |
+5,100
| New | +$454K |
|
79
Cigna
CI
$73.7B
| $439K | 0.14% |
3,000
-20,150
| -87% | -$2.97M |
|
80
HCA Healthcare
HCA
$87.2B
| $379K | 0.12% |
4,262
-32,838
| -89% | -$2.74M |
|
81
Corvus Pharmaceuticals
CRVS
$1.12B
| $282K | 0.09% |
+13,600
| New | +$213K |
|
82
AnaptysBio
ANAB
$1.58B
| $258K | 0.08% |
+9,300
| New | +$217K |
|
83
State Street SPDR S&P Biotech ETF
XBI
$9.95B
| $243K | 0.08% |
+3,500
| New | +$235K |
|
84
Bausch Health
BHC
$2.58B
| $221K | 0.07% |
+20,000
| New | +$275K |
|
85
Exelixis
EXEL
$13.3B
| $214K | 0.07% |
9,870
-51,000
| -84% | -$1.04M |
|
|
ONCE
86
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $213K | 0.07% |
4,000
-10,800
| -73% | -$641K |
|
|
OCRX
87
DELISTED
Ocera Therapeutics, Inc.
OCRX
| $200K | 0.06% |
152,642
-73,800
| -33% | -$94K |
|
88
Acadia Healthcare
ACHC
$2.76B
| – | – |
-44,800
| Closed | -$1.48M |
|
89
Amgen
AMGN
$208B
| – | – |
-4,358
| Closed | -$637K |
|
90
Baxter International
BAX
$13.5B
| – | – |
-4,700
| Closed | -$208K |
|
|
CBIO
91
Crescent Biopharma
CBIO
$537M
| – | – |
-145
| Closed | -$88K |
|
92
Henry Schein
HSIC
$9.77B
| – | – |
-54,060
| Closed | -$3.22M |
|
93
Neurocrine Biosciences
NBIX
$16.8B
| – | – |
-11,500
| Closed | -$445K |
|
94
Penumbra
PEN
$12.7B
| – | – |
-49,500
| Closed | -$3.16M |
|
95
VanEck Pharmaceutical ETF
PPH
$959M
| – | – |
-15,600
| Closed | -$819K |
|
96
Sarepta Therapeutics
SRPT
$1.57B
| – | – |
-8,400
| Closed | -$230K |
|
97
Steris
STE
$22.3B
| – | – |
-16,600
| Closed | -$1.12M |
|
|
ENDP
98
DELISTED
Endo International plc
ENDP
| – | – |
-44,196
| Closed | -$728K |
|
|
MDCO
99
DELISTED
Medicines Co
MDCO
| – | – |
-27,300
| Closed | -$927K |
|
|
ARRY
100
DELISTED
Array Biopharma Inc
ARRY
| – | – |
-28,100
| Closed | -$247K |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q1 2017 Portfolio in Review
As of Q1 2017, Endurant Capital Management held 105 positions worth $311M, up 29% from $242M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Endurant Capital Management deployed $46.5M of net new capital in Q1 2017, opening 32 new positions and adding to 29 existing holdings. Its largest new stake was Universal Health Services: 95,100 shares worth $11.8M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 88% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Encompass Health, an estimated $5.34M trimmed.
- Endurant Capital Management's largest Q1 2017 buy was Universal Health Services: 95,100 shares worth $11.8M.
- Endurant Capital Management added most to Oxford Immunotec Global PLC Ordinary Shares in Q1 2017, an estimated $7.93M increase.
- Endurant Capital Management's biggest Q1 2017 reduction was Encompass Health, cutting an estimated $5.34M.
- Endurant Capital Management fully exited St Jude Medical in Q1 2017, selling an estimated $9.69M.
- Endurant Capital Management's ten largest holdings make up 35% of its $311M portfolio in Q1 2017.
- Endurant Capital Management opened 32 new positions and closed 17 in Q1 2017.
- Endurant Capital Management's portfolio value rose 29% quarter-over-quarter to $311M.
Based on Endurant Capital Management's 13F filing for Q1 2017, filed 15 May 2017.